Fast Facts
If you need to check your facts about the importance of patient engagement activities ahead of a budget, pitch, or sponsorship presentation then submit your request here and an ISPEPer will help you.
Alternatively, you can also submit your own Fast Fact to support the ISPEP community!
Fact:
Active involvement of patients in research can lead to research of greater quality and relevance owing to the unique perspective that users can bring to a research project (Brett et al., 2014).
Fact:
80% of clinical trials are delayed due to recruitment problems and 85% fail to recruit enough patients (Parexel, 2019). Patient and public involvement interventions have been shown to significantly increase the odds of a patient enrolling in a clinical trial (Crocker et al., 2018).
Fact:
"[Improved patient involvement can] make medicine development faster, more efficient, and more productive.” – Hoos et al., 2015
Fact:
“Many patient advocacy organisations today are led by professionals, are meaningful and empowered stakeholders in the development of treatments, and have a large impact on research” – Stein et al., 2018
Fact:
Involvement of patients in the research and development of new medicines is a widely-accepted strategy in the pharmaceutical industry to ensure relevance and suitability of novel treatments (Klingmann et al., 2018).
Fact:
Patient partnerships have been found to be valuable throughout the research process, from planning research to conducting studies and disseminating results (PCORI, 2023).
Medicines Development and R&D
Fact:
"Drugs developed using patient-centric designs were more likely to be launched compared to drugs developed without, with nearly 20 percentage point difference (87%) when compared to the control group (68%)." – The Economist Intelligence Unit
Fact:
Reinforcing patient relevance in evidence generation is a key priority for the EMA’s Regulatory Science Strategy (EMA, 2024).
Fact:
Evidence shows PED is a valuable component of patient-focused drug development; PED was reported as relevant for 39 of 48 (81.3%) drugs approved by FDA in 2019. In the same year, 27 out of 48 (56.3%) labels contained one or more efficacy claims based on COAs (Schultz-Knudsen et al., 2021).
Fact:
HTA frameworks now consider patient experience as one of three ‘pillars’ of quality in healthcare, alongside clinical effectiveness and safety (Sarri et al. 2021).
Fact:
Partner engagement (including engagement with patients and caregivers) can increase acceptability of new care pathways to patients and providers and enhance uptake of effective interventions by health systems (Ballengee et al., 2023).
Fact:
"Drugs developed using patient-centric designs were more likely to be launched compared to drugs developed without, with nearly 20 percentage point difference (87%) when compared to the control group (68%)." – The Economist Intelligence Unit
Fact:
Reinforcing patient relevance in evidence generation is a key priority for the EMA’s Regulatory Science Strategy (EMA, 2024).
Fact:
Evidence shows PED is a valuable component of patient-focused drug development; PED was reported as relevant for 39 of 48 (81.3%) drugs approved by FDA in 2019. In the same year, 27 out of 48 (56.3%) labels contained one or more efficacy claims based on COAs (Schultz-Knudsen et al., 2021).
Fact:
HTA frameworks now consider patient experience as one of three ‘pillars’ of quality in healthcare, alongside clinical effectiveness and safety (Sarri et al. 2021).
Fact:
Partner engagement (including engagement with patients and caregivers) can increase acceptability of new care pathways to patients and providers and enhance uptake of effective interventions by health systems (Ballengee et al., 2023).
Regulatory and Access
Fact:
“Compared with an investment of $100,000 in patient engagement, the NPV and ENPV increases can exceed 500-fold the investment. This ENPV increase is the equivalent of accelerating a pre–phase 2 product launch by 2½ years (1½ years for pre–phase 3)” – Levitan, 2018
Fact:
Slow or failed patient enrolment can cause delays in clinical development; these delays can cost sponsors approximately $500,000 in lost prescription drug or biologic sales for each day that a trial delays a product’s development and launch (Tufts Center for the Study of Drug Development, 2023). Patient engagement can reduce these losses and even accelerate time to market (Crocker et al., 2018) (Hoos et al., 2015).
Fact:
“More than 50% of doctors said that, all else being equal, they were more likely to prescribe medication from a pharma company they considered more patient-centric.” – Lubkeman, 2020
Fact:
“Compared with an investment of $100,000 in patient engagement, the NPV and ENPV increases can exceed 500-fold the investment. This ENPV increase is the equivalent of accelerating a pre–phase 2 product launch by 2½ years (1½ years for pre–phase 3)” – Levitan, 2018
Fact:
Slow or failed patient enrolment can cause delays in clinical development; these delays can cost sponsors approximately $500,000 in lost prescription drug or biologic sales for each day that a trial delays a product’s development and launch (Tufts Center for the Study of Drug Development, 2023). Patient engagement can reduce these losses and even accelerate time to market (Crocker et al., 2018) (Hoos et al., 2015).
Fact:
“More than 50% of doctors said that, all else being equal, they were more likely to prescribe medication from a pharma company they considered more patient-centric.” – Lubkeman, 2020
Return on Investment/Engagement
Click here to view all fast facts.